Exagen Inc (NAS:XGN)
$ 2.75 -0.04 (-1.43%) Market Cap: 47.81 Mil Enterprise Value: 47.91 Mil PE Ratio: 0 PB Ratio: 2.72 GF Score: 70/100

Exagen Inc at Canaccord Genuity Growth Conference Transcript

Aug 09, 2023 / 07:00PM GMT
Release Date Price: $2.57 (-7.22%)
Kyle Mikson
Canaccord Genuity - Analyst

Hi, everyone. Welcome to the Canaccord Genuity Global Growth Conference. I'm Kyle Mikson, I cover life science tools and diagnostics for Canaccord. Please welcome to this fireside chat, with Exagen here, we have the CEO John Aballi and CFO Kamal Adawi. How are you guys doing? Thanks for joining us.

John Aballi
Exagen Inc. - CEO & President

Doing well, Kyle. Thanks for having us.

Questions & Answers

Kyle Mikson
Canaccord Genuity - Analyst

And Exagen is really the leading, I would say, autoimmune testing company, and we'll find a more -- I mean, you really specialize on lupus right now, but has a number of things in the works, I suppose. So maybe on that note, actually, John, I wanted to start with like telling us like an overview of Exagen, maybe like this rheumatological market that you're targeting.

John Aballi
Exagen Inc. - CEO & President

Certainly. Thanks again for having us, pleasure to be here. Happy to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot